Introduction: Botulinum toxin is crucial for reducing sequelae in movement disorders such as Parkinson's. It blocks muscle contractions and improves quality of life, being used in both aesthetic and medical treatments. Methodology: A non-experimental longitudinal design was adopted, observing variables at multiple time points without manipulation. A mixed approach (qualitative and quantitative) was used with adults over 30 years old without Parkinson's history. The review included documents from PubMed, Scopus, and Scielo, applying rigorous inclusion and exclusion criteria. Objective: To evaluate the efficacy of botulinum toxin in treating abnormal movements in Parkinson's and understand its long-term effects. Results: Botulinum toxin type A reduces tremors by blocking acetylcholine. It improves motor symptoms of Parkinson's and essential tremor but requires frequent and costly treatments. There is a risk of developing antibodies that decrease its effectiveness. Discussion: It offers significant benefits, but its high cost and the need for frequent treatments are challenges. Patients report satisfaction in short-term studies, but more long-term research is needed. Conclusions: Promising for movement disorders, especially Parkinson's, although limited by cost and duration of effect. Future research should seek to extend therapeutic effects and reduce costs.